Vikash Kumar Dubey
Overview
Explore the profile of Vikash Kumar Dubey including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
121
Citations
3650
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Prasad R, Prerna K, Temgire M, Banerjee P, Kumari R, Kundu G, et al.
Adv Healthc Mater
. 2024 Dec;
14(3):e2401233.
PMID: 39629548
Optically active ultrabright imaging agents are shown to delineate tumor location with deep tissue visualization in pre noclinical tumor models. NanoGhosts (NGs) particles are reconstructed from the cell membrane and...
2.
Menpadi N, Chandra P, Dubey V
J Basic Microbiol
. 2024 Nov;
65(3):e2400655.
PMID: 39604153
We have earlier reported novel anti-leishmanial molecules, veratramine and hupehenine, targeting dephospho-coenzyme A kinase of the parasite. In our current investigation, we assessed the efficacy of these two steroidal alkaloids,...
3.
Bora K, Sarma M, Kanaujia S, Dubey V
Free Radic Biol Med
. 2024 Oct;
225:275-285.
PMID: 39388970
The dual-target inhibitors (ZINC000008876351 and ZINC000253403245) were identified by utilizing an advanced computational drug discovery method by targeting two critical enzymes such as FeSODA (Iron superoxide dismutase) and TryR (Trypanothione...
4.
Sarma M, Bora K, Ranjan P, Dubey V
FEBS Lett
. 2024 Sep;
599(3):367-380.
PMID: 39266470
Drug repurposing has emerged as an effective strategy against infectious diseases such as visceral leishmaniasis. Here, we evaluated four FDA-approved drugs-valrubicin, ciclesonide, deflazacort, and telithromycin-for their anti-leishmanial activity on Leishmania...
5.
Ranjan P, Sarma M, Dubey V
Int J Biol Macromol
. 2024 Sep;
279(Pt 3):135400.
PMID: 39245106
Citrate synthase is a crucial enzyme in the TCA cycle and represents a potential therapeutic target. However, knowledge about this enzyme in Leishmania parasites remains limited. In this study, we...
6.
Bora K, Sarma M, Kanaujia S, Dubey V
Sci Rep
. 2023 Oct;
13(1):18363.
PMID: 37884555
Antioxidant defense mechanisms are important for a parasite to overcome oxidative stress and survive within host macrophage cells. Mitochondrial iron superoxide dismutase A (FeSODA) and trypanothione reductase (TR) are critical...
7.
Singh G, Thomas J, Wadhawa S, Kashyap A, Rahaman S, Borkotoky S, et al.
Mol Divers
. 2023 Sep;
28(5):2847-2862.
PMID: 37749454
Covid-19 was declared a world pandemic. Recent studies demonstrated that Covid-19 impairs CNS activity by crossing the blood-brain barrier and ensuing cognitive impairment. In this study, we have utilized Covid-19...
8.
Ranjan P, Dubey V
J Cell Biochem
. 2023 Aug;
124(9):1404-1422.
PMID: 37566640
In this study, we have screened a large number of Food and Drug Administration-approved compounds for novel anti-leishmanial molecules targeting the citrate synthase enzyme of the parasite. Based on their...
9.
Sarma M, Borkotoky S, Dubey V
J Biomol Struct Dyn
. 2023 Jul;
42(14):7628-7636.
PMID: 37491862
In the pursuit of developing novel anti-leishmanial agents, we conducted an extensive computational study to screen inhibitors from the FDA-approved ZINC database against glutathione synthetase. The three-dimensional structure of glutathione...
10.
Bhattacharjee S, Dubey V, Mukhopadhyay A, Chakraborty S
Phys Rev E
. 2023 Jul;
107(6-1):064405.
PMID: 37464624
Even though the existence of nonconvergent evolution of the states of populations in ecological and evolutionary contexts is an undeniable fact, insightful game-theoretic interpretations of such outcomes are scarce in...